Lisa Vinal, NP
Family · Millinocket, MENPI 1316211469
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 127 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 21.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,487 and has fallen 80.8% since, to $286 in 2025. Among family clinicians in ME with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 127 payments — averaging $32.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Myriad Genetic Laboratories, Inc.$875
- Sumitomo Pharma America, Inc.$442
- Dendreon Pharmaceuticals LLC$371
- Johnson & Johnson$282
- GSK$228
- Bayer$185
- plus $2K from 24 others
What the payments were for
- Food & beverage$4,147100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Myriad Genetic Laboratories, Inc. | 12 | $875 |
| Sumitomo Pharma America, Inc. | 19 | $442 |
| Dendreon Pharmaceuticals LLC | 10 | $371 |
| Johnson & Johnson | 15 | $282 |
| GSK | 14 | $228 |
| Bayer | 6 | $185 |
| Novo Nordisk | 5 | $173 |
| AstraZeneca(2 entities) | 3 | $171 |
| AbbVie | 6 | $115 |
| Urogen Pharma, Inc. | 2 | $109 |
| Janssen Scientific Affairs, LLC | 1 | $107 |
| Nevro Corp. | 1 | $103 |
| Boston Scientific | 1 | $103 |
| Sanofi-aventis U.S. LLC | 1 | $90 |
| Pfizer | 5 | $87 |
| Amgen | 1 | $87 |
| Merck | 4 | $79 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $75 |
| Esperion Therapeutics, Inc. | 1 | $74 |
| Verity Pharmaceuticals Inc. | 3 | $73 |
| Astellas Pharma US Inc | 3 | $58 |
| Procept Biorobotics Corporation | 2 | $57 |
| Tolmar, Inc. | 3 | $49 |
| Abbott | 2 | $42 |
| Teleflex LLC | 1 | $28 |
| Photocure Inc | 1 | $23 |
| Sanofi Pasteur Inc. | 1 | $19 |
| Ferring Pharmaceuticals Inc. | 1 | $17 |
| Coloplast | 1 | $15 |
| Blue Earth Diagnostics | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,147 in reported general payments places this provider in the 95th percentile of 545 family providers in Maine.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 24 | $14,566 |
| GemtesaVibegron | 33 | $14,039 |
| Tamsulosin Hcl | 346 | $4,639 |
| Solifenacin Succinate | 72 | $4,242 |
| Tolterodine Tartrate ErTolterodine Tartrate | 42 | $3,121 |
| Estradiol | 43 | $2,816 |
| Oxybutynin Chloride ErOxybutynin Chloride | 118 | $1,633 |
| Methenamine Hippurate | 33 | $1,408 |
| Finasteride | 107 | $1,282 |
| Fosfomycin Tromethamine | 12 | $1,198 |
| NitrofurantoinNitrofurantoin Macrocrystal | 20 | $1,037 |
| Ciprofloxacin Hcl | 142 | $813 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 24 | $579 |
| Testosterone Cypionate | 16 | $439 |
| Dutasteride | 22 | $391 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $58 | $14,56624 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $442 | $14,03933 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 545 family providers in Maine.
Other family in Millinocket
- Mia RapollaFalmouth$193K
- Patti DupreyKennebunk$35K
- Amanda WilliamsPortland$8K
- Jamie PiacentiniScarborough$6K
- Rosemary PainePortland$6K
- Brea SwihartAugusta$5K
- Kristen Schroeder-CyrBrunswick$5K
- Liana KellyBrunswick$5K
- Natalie BubierLewiston$5K
- Holly JamesYork$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.